Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for patients with genetically defined cancers, with an emphasis on pediatric and adult populations with rare or difficult-to-treat tumors. The company operates within the oncology and precision medicine segments of the biotechnology industry, targeting cancers driven by specific oncogenic mutations. Its core strategy is to develop highly selective small-molecule therapeutics designed to inhibit key molecular drivers of disease while improving safety and tolerability.
The company’s primary value driver is its lead product candidate, tovorafenib (DAY101), an oral, brain-penetrant, selective pan-RAF kinase inhibitor being developed primarily for pediatric low-grade glioma and other RAF-altered solid tumors. Day One was founded in 2018 and evolved from a research-focused startup into a publicly traded company following its initial public offering in 2021. Since inception, it has positioned itself as a mission-driven organization addressing significant unmet needs in pediatric oncology, a field historically underserved by drug development efforts.
Business Operations
Day One’s operations center on research and development activities, including preclinical research, clinical trials, regulatory engagement, and preparation for potential commercialization. The company currently operates as a single-reportable operating segment focused on oncology drug development, with revenues primarily consisting of collaboration and licensing-related income, rather than product sales, as its lead asset remains under regulatory review or development depending on jurisdiction and indication.
The company controls proprietary drug discovery and development capabilities, including medicinal chemistry, translational biology, and clinical development expertise. Clinical operations are conducted through a combination of internal teams and third-party contract research organizations. Day One has established relationships with academic institutions, clinical trial networks, and regulatory authorities to support its development programs, and its intellectual property portfolio underpins its core therapeutic candidates.
Strategic Position & Investments
Day One’s strategic direction emphasizes advancing precision oncology therapies for patient populations with limited treatment options, particularly children with cancer. Its near- and mid-term growth strategy centers on advancing tovorafenib (DAY101) through late-stage clinical development, regulatory submissions, and potential commercialization, while expanding its clinical utility across multiple RAF-altered tumor types. The company also maintains a pipeline of earlier-stage discovery programs aimed at genetically defined cancers.
The company has made targeted investments in expanding its clinical development infrastructure and regulatory capabilities in anticipation of commercial launch. While Day One does not operate as a diversified holding company, it maintains full ownership of its core development programs rather than a broad portfolio of subsidiaries. Its strategic positioning is reinforced by orphan drug designations and other regulatory incentives associated with rare pediatric oncology indications.
Geographic Footprint
Day One Biopharmaceuticals is headquartered in South San Francisco, California, a major biotechnology hub within the United States. Its primary operations, including executive leadership, research oversight, and clinical development management, are based in this region. The company benefits from proximity to academic medical centers, biotechnology talent, and industry partners.
Internationally, Day One’s presence is primarily operational rather than physical, with clinical trials conducted across North America, Europe, and other select global regions through investigative sites and research partners. While the company does not maintain extensive overseas facilities, its global clinical and regulatory activities support its strategy to pursue approvals and future commercialization in multiple international markets.
Leadership & Governance
Day One is led by an experienced management team with backgrounds in oncology drug development, regulatory affairs, and biopharmaceutical commercialization. The leadership team emphasizes a patient-centric philosophy focused on delivering transformative therapies to underserved cancer populations, particularly children. Governance practices align with those of publicly traded U.S. biotechnology companies, with oversight provided by an independent board of directors.
Key executives include:
- Jeremy Bender – President and Chief Executive Officer
- Samuel C. Blackman, M.D., Ph.D. – Co-Founder and Chief Medical Officer
- Michael J. Pelletier – Chief Operating Officer
- Daniel J. Flynn – Chief Financial Officer
- Jeffrey M. Leung – Chief Legal Officer and Corporate Secretary
The leadership team’s strategic vision centers on disciplined clinical execution, regulatory rigor, and long-term value creation through precision oncology innovation.